Date: October 26th, 2021 – October, 28th, 2021

Contact: emily.lincoln@hansonwade.com

Built with Alexion, Apellis and Annexon, the 5th Complement-based Drug Development Summit returns for its fifth year as the definitive industry dedicated forum to maximize complement-targeting in the pan-disease setting. With pivotal clinical readouts poised to be released in 2021, this year’s summit will once again unite thought leaders in complement-based drug development. Expect to be involved in interactive discussions on:- How dysregulated complement signalling contributes to disease and how to identify novel drug targets up and downstream of C3 and C5- Preclinical and clinical pipeline progress of diverse drug modalities, including gene therapy approaches, small molecule inhibitors, antibodies, protease inhibitors, nucleic acids & more!- Leveraging complement proteins in precision-based medicine as disease biomarkers and companion diagnostics- Addressing clinical challenges of complement-targeted therapeutic sequencing, combinations and timing of administration- Expanding the clinical utility of complement inhibitors across rare diseases, as well as autoimmune, ophthalmic, neurological and cancer settingsJoin us on our dedicated virtual platform as we unite drug developers and researchers in maximizing complement-targeting in the pan-disease setting!